Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096855 | 0.81 | KDR (0.32) | — | |
| SCHEMBL21709863 | 0.77 | NOS3 (0.31) | — | |
| SCHEMBL17075277 | 0.77 | CCR1 (0.41) | ALDH1A1 | |
| SCHEMBL22096810 | 0.76 | ALOX12 (0.49) | SMN1; SMN2ALOX12MAPTALDH1A1FGF23 | |
| SCHEMBL21173560 | 0.73 | ALDH1A1 (0.33) | ALDH1A1FGF23KDM4EALOX15L3MBTL1 | |
| SCHEMBL21709866 | 0.69 | NOS2 (0.56) | MAPTKDM4E | |
| SCHEMBL12479706 | 0.68 | HTT (0.33) | SMN1; SMN2ALOX12MAPTALDH1A1FGF23 | |
| SCHEMBL12479704 | 0.68 | HTT (0.33) | SMN1; SMN2ALOX12MAPTALDH1A1FGF23 | |
| SCHEMBL22096897 | 0.67 | NOS3 (0.34) | KDM4E | |
| SCHEMBL16962638 | 0.64 | MAPT (0.58) | SMN1; SMN2MAPTALDH1A1FGF23KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889561-B2 | Process of making somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | SMN1; SMN2 869/4885ALOX12 1316/4885MAPT 3475/4885 |
| US-10889561-B2 | Process of making somatostatin modulators | SSTR5, SSTR4, SSTR2 | SMN1; SMN2 869/4885ALOX12 1316/4885MAPT 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.